A 24‐week, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of GSK573719/GW642444 inhalation powder and the individual components delivered once‐daily via a novel dry powder inhaler in subjects with chronic obstructive pulmonary disease

Authors
Category Primary study
Registry of TrialsGSK Study Register
Year 2011
This article has no abstract
Epistemonikos ID: 6beb4b73623b8995d09895cd0a78e8e56d79f1e4
First added on: Sep 04, 2019